Bicara Therapeutics
https://www.bicara.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Bicara Therapeutics
Merus Gains Momentum Ahead Of Keytruda Combination Results
Results in head and neck cancer for its lead bispecific antibody are expected at ASCO, with signs the FDA could accept an accelerated approval application based only on overall response rate data.
Under LG Chem’s Wing, AVEO Oncology Steps On R&D Gas Pedal
With the integration with new parent LG Chem having gone "smoothly," AVEO Oncology is accelerating R&D efforts by beginning a pivotal Phase III trial with a combination of its novel candidate for head and neck cancer.
VC Fundraising Fell In Q4 But There Are Glimmers Of Hope For 2024
Evaluate’s fourth quarter data show that biopharma venture capital fundraising fell from $4.28bn in in Q3, but there was a rise in smaller deals and financial market conditions are poised for a turnaround.
Bicara Scoops Up $165m And Heads To Pivotal Trials
The group’s second major venture round this year makes it one of the most successful fundraisers of 2023.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice